Skip to content

Trial Summary

A Randomised Phase III Double-Blind Placebo-Controlled Study of regorafenib in Refractory Advanced Gastro-Oesophageal Cancer (AGOC)

Acronym:

INTEGRATE 2B

ACTRN/NCT /ethics:

ACTRN12616000420448

Scientific title:

Randomised Phase III Controlled Trials of Regorafenib containing regimens versus standard care in Refractory Advanced Gastro-Oesophageal Cancer (AGOC)

Sponsor / Cooperative group:

Bayer HealthCare Pharmaceuticals Inc

Trial & Patient Characteristics

Cancer TypeStomach & Oesophageal
Trial TypeTreatment
PhasePhase III
Age Range18 years and older
SexAll
Tumour Stream Advanced Gastro-Oesophageal Cancer
Cancer StageLocally Advanced, Metastatic or Widespread
Anticipated Start Date2016-11-06
Anticipated End Date-

Participating Hospitals

HospitalFlinders Medical Centre
Clinical Trial CoordinatorHannah Adelson
EmailHannah.adelson@sa.gov.au
Phone08 8206 4835
Principal InvestigatorDr Sina Vatandoust
Recruitment StatusNot Yet Recruiting